elbasvir + grazoprevir + sofosbuvir

This entry refers to a queried combination of three direct-acting antiviral agents: elbasvir, grazoprevir, and sofosbuvir, used for the treatment of chronic hepatitis C virus (HCV) infection. Elbasvir is an NS5A inhibitor that prevents HCV RNA replication and virion assembly. Grazoprevir is an NS3/4A protease inhibitor that prevents cleavage of polyproteins necessary for viral replication. Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor. Based on the provided search results, this specific three-drug combination is not identified as a standard fixed-dose formulation. Elbasvir and grazoprevir are available together in the fixed-dose combination product Zepatier, while sofosbuvir is a component in other HCV combination therapies such as Epclusa (sofosbuvir/velpatasvir).